Le Dichloroacétate de Sodium à l'aide de cas 2156-56-1

what is  of  Sodium Dichloroacetate with cas 2156-56-1

Sodium dichloroacetate (DCA) is a mitochondrial pyruvate dehydrogenase kinase inhibitor, and is an orally absorbable small molecular compound for MELAS syndrome, and children with congenital lactic acidosis and other diseases that are treated in the clinic. Recent studies had found that DCA acts as a potential vasoprotective agent by inhibiting PDK2 and reducing coronary endarterium proliferation. Further, DCA promotes brain regeneration after cerebral ischemia, which indicates that DCA might play an important role in VD.

CAS: 2156-56-1
Pureté: 99%
MF: C16H16O3
Le Dichloroacétate de Sodium à l'aide de cas 2156-56-1
Vous devez remplir ce champ
Veuillez saisir une adresse e-mail valide.
Vous devez remplir ce champ
Vous devez remplir ce champ

Quick Details of  Sodium Dichloroacetate with cas 2156-56-1

Cas :2156-56-1
MF:C2H3Cl2NaO2
MW:152.93
EINECS: 218-461-3
Melting point: 198 ° C (dec.) (lit.)
Storage conditions: Inert atmosphere, 2-8 ° C
Solubility: Methanol (Slightly), Water (Slightly)
Form: Powder

Specification of  Sodium Dichloroacetate with cas 2156-56-1

Article
Spécifications
Résultats
Apparence
White powder or crystalline powder
Confirme
La pureté, la %
≥99.5
99.99
Le point de fusion de gamme , ℃
64.0~67.0
Confirme
Loss on drying , %
Et ≤0,5
0.030
Moisture , %
Et ≤0,5
0.047

Emballage 

25kgs/tambour, 9tons/20'container

L'utilisation de la 

Sodium dichloroacetate is an inhibitor of mitochondrial pyruvate dehydrogenase kinase.

Le Dichloroacétate de Sodium à l'aide de cas 2156-56-1
Vous devez remplir ce champ
Veuillez saisir une adresse e-mail valide.
Vous devez remplir ce champ
Vous devez remplir ce champ

Vous aimerez aussi